PubRank

Dana C Miskulin

Author PubWeight™ 30.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 2014 5.01
2 Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 2014 1.64
3 The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010 1.59
4 Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis 2007 1.53
5 Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2011 1.47
6 Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008 1.46
7 Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003 1.17
8 Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2011 1.13
9 Predialysis health, dialysis timing, and outcomes among older United States adults. J Am Soc Nephrol 2013 1.10
10 Imperial or empirical measures of dialysis quality? Am J Kidney Dis 2007 1.09
11 Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis 2010 1.05
12 The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. J Am Geriatr Soc 2008 1.05
13 Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. BMC Nephrol 2012 1.00
14 Predialysis systolic BP variability and outcomes in hemodialysis patients. J Am Soc Nephrol 2014 0.95
15 Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009 0.94
16 Variation in fistula use across dialysis facilities: is it explained by case-mix? Clin J Am Soc Nephrol 2010 0.93
17 Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011 0.87
18 Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months. BMC Nephrol 2013 0.87
19 Both patient and facility contribute to achieving the Centers for Medicare and Medicaid Services' pay-for-performance target for dialysis adequacy. J Am Soc Nephrol 2011 0.87
20 Hypertension in individuals at risk for autosomal dominant polycystic kidney disease: to screen or not to screen? Am J Kidney Dis 2005 0.80
21 Updated comorbidity assessments and outcomes in prevalent hemodialysis patients. Hemodial Int 2010 0.80
22 Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007 0.77
23 Anemia management in chronic kidney disease: bursting the hemoglobin bubble. Ann Intern Med 2010 0.77
24 Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients. Clin J Am Soc Nephrol 2010 0.76
25 Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease. Blood Press Monit 2011 0.76
26 Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. Medicine (Baltimore) 2017 0.75
27 Making an earlier diagnosis of ADPKD: implications for the treatment of hypertension. Nephrol News Issues 2006 0.75